Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Renal Cell Carcinoma

Kazunari Sato,1,3 Norihiko Tsuchiya,1,3 Ryusei Sasaki,1 Naotake Shimoda,1 Shigeru Satoh,1 Osamu Ogawa2 and Tetsuro Kato1,4

1Department of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543 and 2Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8397

Neovascularization, an essential event for the growth of solid tumors, is regulated by a number of angiogenic factors. One such factor, vascular endothelial growth factor (VEGF), is considered to exert a potent angiogenic activity, as indicated by immunohistochemical and molecular evidence. In this study we investigated the serum VEGF level (s-VEGF) in patients with renal cell carcinoma (RCC). s-VEGF in peripheral blood samples was analyzed in 40 RCC patients and 40 patients without cancer (controls) using a sandwich enzyme-linked immunoassay. In 20 RCC patients, serum samples were obtained separately from the bilateral renal veins. s-VEGF was also measured before, 4 and 8 weeks after nephrectomy in 11 patients. There were significant differences in s-VEGF between the RCC patients and the controls (207.3±32.9 vs. 71.5±9.1 pg/ml, mean±SE) (P<0.005), between the tumor-bearing renal veins and the contralateral ones (P<0.01), between the pre- and post-nephrectomy situations (P<0.01) and among the various parameters of tumor status such as tumor extent (P<0.001) and existence of metastasis (P<0.001), s-VEGF significantly correlated with the tumor volume obtained by a three-dimensional measurement (r=0.802, P<0.0001). The sensitivity and specificity of s-VEGF at the cut-off level of 100 pg/ml, as determined by the receiver-operating-characteristics curve, were 80.0% and 72.5%, respectively. The results indicate that tumor tissue of RCC liberates VEGF into the systemic blood flow and that s-VEGF is a possible marker for RCC.

Key words: VEGF — Serum — Renal cell carcinoma

MATERIALS AND METHODS

Blood samples were obtained before breakfast from the peripheral veins of 40 patients with RCC and 40 control subjects with no evidence of cancer or inflammatory disease. The control subjects consisted of 30 males and 10 females, with a mean age of 46.1±9.2 (SD) years ranging from 33 to 86. Characteristics of the patients are summarized in Table I. No significant difference in age or sex was observed between RCC patients and the controls. Evaluations of clinical status, including TNM classification of UICC,15) tumor volume and tumor progression, were based on the radiological findings including plain X-ray, RI imaging, CT scan and MR imaging. The sum of tumor volume, including metastatic lesions, in each patient was calculated three-dimensionally from CT scan and/or MR imaging films. Radical nephrectomy was performed on 30 RCC patients, partial nephrectomy on 3 and selective embolization of the renal artery on 4. The remaining 3 patients underwent palliative treatments because of a far advanced stage of the disease. Sampling of the peripheral blood in the 40 RCC patients was performed before initiation of the treatments. In 11 of these patients, blood samples were also obtained 4 and 8 weeks after radical (8

874
Table I. Clinical and Pathological Findings of 40 RCC Patients

| Tumor volume | 182.8±47.3 (4.3–1,267.5) ml$^a$ |
|--------------|---------------------------------|
| Primary tumor |                                 |
| T1           | 4 (3)$^b$                        |
| T2           | 25 (23)$^b$                      |
| T3           | 8 (7)$^b$                        |
| T4           | 3 (0)$^b$                        |
| Distant metastasis |              |
| M0           | 28 (27)$^b$                      |
| M1           | 12 (6)$^b$                       |
| Pathological grade |              |
| G1           | 20 (20)$^b$                      |
| G2           | 10 (10)$^b$                      |
| G3           | 3 (3)$^b$                        |

$^a$ Patients: age 60.8±10.8 (37–83) (mean±SD), M:F=28:12.

$^b$ No. of patients subjected to partial or total nephrectomy.

RESULTS

The mean serum VEGF level of RCC patients (207.3±32.9 pg/ml) was significantly higher than that of the controls (71.5±9.1 pg/ml) (P<0.01) (Fig. 1). The sensitivity and specificity of serum VEGF at the cut-off level of 100 pg/ml given by the ROC curve were 80.0% and 72.5%, respectively. A serum VEGF level above the cut-off level was found in 29 (72.5%) of the RCC patients and in 8 (20%) of the controls (P<0.001). The serum VEGF level in the tumor-bearing renal vein was higher than that in the contralateral vein in 17 (85%) of 20 RCC patients, with a significant difference between the ipsilateral (244.7±22.6 pg/ml) and contralateral veins (229.6±21.2 pg/ml) (P<0.01). Correlations between the serum VEGF levels and parameters of the tumor status, such as existence of distant metastasis, grade and clinical stage, are shown in Table II. The mean serum VEGF levels of patients with non-invasive (T1–2) and invasive (T3–4) tumors were significantly increased as compared to that of the controls (P<0.05 and P<0.001, respectively) and a significant difference was also observed between the patients with non-invasive and invasive tumors (P<0.001). The mean serum VEGF level in the patients with distant metastasis (349±93.7 pg/ml) was markedly higher than that in the patients without metastasis (150.6±16.0 pg/ml) (P<0.001). A trend of increased serum VEGF levels was seen in the patients with higher-grade tumors. The serum VEGF level was significantly correlated with the tumor volume calculated from the three-dimensional measurement (r=0.802, P<0.0001) (Fig. 2). A decrease of serum VEGF level was seen within 8 weeks after nephrectomy in all of the 11 patients analyzed, the postoperative VEGF level (56.3±11.0 pg/ml) being significantly lower than the preoperative one (156±24.8 pg/ml) (P<0.005). Seven (78%) of 9 patients with a preoperative VEGF level above the given cut-off level (100 pg/ml) showed a normalization (<100 pg/ml) of VEGF level after nephrectomy (Fig. 3).

DISCUSSION

Four isoforms of VEGF are regulated from a single gene by an alternative splicing mechanism, and produce characteristic signal peptides. The isoforms VEGF$_{121}$ and VEGF$_{165}$, having a low affinity for heparin, are thought to be liberated into the blood circulation as they freely diffuse within the adjacent tissue after secretion by VEGF-producing cells.$^{16}$ Recent studies revealed an elevated serum VEGF level in patients with several kinds of cancers. Kumar et al., showed that the serum VEGF level in patients with colorectal cancer was significantly elevated and correlated with clinical stage.$^{17}$ Takigawa et al., reported that the serum VEGF level in patients with lung...
cancer was significantly elevated, but there were no significant correlations between the serum VEGF level and pathological or clinical parameters. As for RCC, overexpression of the VEGF gene has been observed, but the serum level of VEGF protein has yet to be determined.

In this study, we found that the serum VEGF level in patients with RCC was significantly higher than that in the controls, the trend being more significant in higher stage tumors, and correlated well with the tumor volume. To our knowledge, this is the first document that describes a significant correlation between the serum level of angiogenic
Factors and the tumor volume assessed by a three-dimensional measurement. We also found that the VEGF level in the renal vein of the tumor-bearing kidneys was higher than that of the contralateral normal kidneys in 85% of the cases, though the difference was not large, and that the serum VEGF level significantly decreased within 8 weeks after resection of the tumors. These findings indicate the possible utility of VEGF as a biological marker of RCC.

It has been noted that VEGF liberated into the blood circulation loses its biological activity owing to immediate binding to α2-macroglobulin and that tumor cells generally secrete various cytokines which in turn induce the expression of VEGF. These results imply that the serum VEGF level in the tumor-bearing renal vein does not represent the gross amount of VEGF secreted from the RCC cells, resulting in the marginal difference in serum VEGF levels between the ipsilateral and contralateral renal veins, as observed in the present study. On the other hand, angiogenesis associated with VEGF expression occurs in various physiological events such as wound healing or formation of the endometrium and placenta. An increased serum VEGF level has been observed for more than 3 weeks after traumatic injury. These documents also support our finding that a long period of over 4 weeks was required for normalization of the serum VEGF level after nephrectomy, a surgical trauma associated with wound healing. Finally, the serum VEGF detected in our control subjects may have come from physiological events associated with or without angiogenesis. In either case, however, it has been demonstrated by biochemical and immunohistochemical means that the cancer cells themselves produce VEGF in RCC. Our previous study showed that tumor tissue had a VEGF mRNA signal intensity of over 3 times that of adjacent normal tissue in 60% of RCCs, and the amount of mRNA expression per tumor volume did not vary in tumors with various characteristics. Consequently the increase of serum VEGF observed in the present study reflects the VEGF secreted from the tumor cells.

The biological significance of the elevated serum VEGF level has not yet been fully clarified. It has been reported that the VEGF concentration in glioma and breast cancer correlates with the microvessel density in tumor tissues, which in turn correlates with tumor progression. In the previous study, we demonstrated a significant correlation between the intensity of VEGF gene expression and the microvessel density in RCC. Thus, an elevated serum level may indicate an increased microvessel density and at the same time a malignant potential of individual tumors. Previously, immunohistochemical and serological investigations on gastrointestinal and ovarian cancer revealed a significant correlation between the VEGF status and the patient’s outcome. Though the present study could not provide the patient’s outcome because of the short follow-up period, the serum VEGF level was well correlated with the extent, histological grade and volume of RCCs. This suggests the possibility that the serum VEGF level could be used as a prognostic parameter for RCC. In fact, we have experienced a few cases in which an increase of normalized serum VEGF level during follow-up was associated with new development of distant metastases (data not shown). Further studies with a larger number of patients and long-term observation are justified to assess the usefulness of serum VEGF level as prognostic and a follow-up marker for RCC.

Fibroblast growth factor-2 (FGF-2), along with VEGF, is another representative angiogenic factor which has been widely investigated in various tumors. Some investigators have noted an elevated serum level of FGF-2 in patients with malignant tumors including RCC and breast cancers. Fujimoto et al. reported that 53.8% of RCC patients showed an increased serum FGF-2 level, which correlated with histological findings such as venous invasion and grade of the tumors. But they did not provide any information on the FGF-2 level of normal subjects or an adequate cut-off level. Although overexpression of FGF-2 has been observed in some cell lines of RCC, it has not been established whether the human RCC tumor tissues express a greater amount of FGF-2 mRNA than the corresponding normal kidney tissues. Immunohistochemical studies have shown that immunoreactivity against FGF-2 is found in both the blood vessel wall and the extracellular matrix in most RCCs, but cytoplasmic FGF-2 is present in only 16% of the tumors. We have also failed to detect overexpression of FGF-2 gene in RCC tissues and to find any difference in the serum FGF-2 protein levels between...
RCC patients and the controls (14.4±1.9 vs. 14.7±3.0 pg/mL; details will be published elsewhere). These findings suggest that the serum FGF-2 level is unsuitable as a tumor marker of RCC.

The present study showed that the serum VEGF level correlated well with the tumor status, indicating tumor extent, volume, clinical stage and existence of metastasis, and significantly decreased after resection of the tumors. We conclude that serum VEGF could be a useful marker for malignant potential of RCC. In addition, considering the recent experimental advances in antiangiogenic therapy for solid tumors, serum VEGF could be useful to monitor the therapeutic effect of novel antiangiogenic substances.

ACKNOWLEDGMENTS

This study was supported by Grants-in-Aid for Scientific Research (No. 08457419, 09557129, 10470330) from the Ministry of Education, Science, Sports and Culture of Japan.

(Received March 5, 1999/Revised May 31, 1999/Accepted June 8, 1999)

REFERENCES

1) Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285, 1182–1186 (1971).
2) Yoshino, S., Kato, M. and Okada, K. Prognostic significance of microvessel count in low stage renal cell carcinoma. Int. J. Urol., 2, 156–160 (1995).
3) Li, V. W., Folkterth, R. D., Watanabe, H., Yu, C., Rupnick, M., Barnes, P., Scott, R. M., Black, P. M., Sallan, S. E. and Folkman, J. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. Lancet, 344, 82–86 (1994).
4) Takahashi, Y., Kitada, Y., Bucana, C. D., Cleary, K. R. and Ellis, L. M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation. Cancer Res., 55, 3964–3968 (1995).
5) Weidner, N., Semple, J. P., Welch, W. R. and Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med., 32, 1–8 (1991).
6) Toi, M., Kashiwani, J. and Tomimaga, T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int. J. Cancer, 55, 371–374 (1993).
7) Delahunt, B., Benthwaite, P. B. and Thornton, A. Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br. J. Urol., 80, 401–404 (1997).
8) Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S. and Dvorak, H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 219, 983–985 (1983).
9) Platte, K. H., Breiter, G., Welch, H. A., Mennel, H. D. and Risau, W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature, 356, 845–848 (1992).
10) Sato, K., Terada, K., Sugiyama, T., Takahashi, S., Saito, M., Moriyama, M., Kinunuma, H., Suzuki, Y., Kato, M. and Kato, T. Frequent overexpression of vascular endothelial growth factor in human renal cell carcinoma. Tohoku J. Exp. Med., 173, 355–360 (1994).
11) Takahashi, A., Sasaki, H., Kim, S. J., Tobisu, K., Kakizoe, T., Tsukamoto, T., Kumamoto, Y., Sugimura, T. and Terada, M. Markedly increased amount of messenger RNAs for endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res., 54, 4233–4237 (1994).
12) Takano, S., Yoshii, Y., Kondo, S., Suzuki, H., Maruno, T., Shirai, S. and Nose, T. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res., 56, 2185–2190 (1996).
13) Toi, M., Kondo, S. and Suzuki, H. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer, 77, 1101–1106 (1996).
14) Kondo, S., Asano, M. and Matsuo, K. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim. Biophys. Acta, 1221, 211–214 (1993).
15) Hermanek, P. and Sobin, L. H. ed. “UICC TNM Classification of Malignant Tumors,” 4th Ed., 2nd Rev. (1992). Springer-Verlag, Berlin.
16) Park, J. E., Keller, G. A. and Ferrara, N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell, 4, 1317–1326 (1993).
17) Kumar, H., Heer, K., Lee, P. W., Duthie, G. S., MacDonald, A. W., Greenman, J., Kerin, M. J. and Monson, J. R. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin. Cancer Res., 4, 1279–1285 (1998).
18) Takigawa, N., Segawa, Y., Fujimoto, N., Hotta, K. and Eguchi, K. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res., 18, 1251–1254 (1998).
19) Soker, S., Svahn, C. M. and Neufeld, G. Vascular endothelial growth factor is inactivated by binding to alpha 2-macroglobulin and the binding is inhibited by heparin. J. Biol. Chem., 268, 7685–7691 (1993).
20) Cohen, T., Nahari, D., Cerem, L. W., Neufeld, G. and Levi, B. Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem., 271, 736–741 (1996).
21) Grad, S., Ertel, W., Keel, M.,Infanger, M., Vonderschmitt, D. J. andMaly, F. E. Strongly enhanced serum levels of vascular endothelial growth. Clin. Chem. Lab. Med., 36,
22) Torry, D. S. and Torry, R. J. Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta. *Am. J. Reprod. Immunol.*, **37**, 21–29 (1998).

23) Sasaki, R. Microvessel count and vascular endothelial growth factor in renal cell carcinoma. *Jpn. J. Urol.*, **87**, 1032–1040 (1996).

24) Hyodo, I., Doi, T., Endo, H., Hosokawa, Y., Nishikawa, Y.,Tanizumi, M., Jinno, K. and Kotani, Y. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. *Eur. J. Cancer*, **34**, 2041–2045 (1998).

25) Tempfer, C., Obermaier, A., Hefler, L., Haeusler, G., Gitsch, G. and Kainz, C. Vascular endothelial growth factor serum concentrations in ovarian cancer. *Obstet. Gynecol.*, **92**, 360–363 (1998).

26) Fujimoto, K., Ichimori, Y., Yamaguchi, H., Arai, K., Futami, T., Ozono, S., Hirao, Y., Kakizoe, T., Terada, M. and Okajima, E. Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma. *Jpn. J. Cancer Res.*, **86**, 182–186 (1995).

27) Sliutz, G., Tempfer, C., Obermaier, A., Dadak, C. and Kainz, C. Serum evaluation of basic FGF in breast cancer patients. *Anticancer Res.*, **15**, 2675–2678 (1995).

28) Singh, R. K., Bucana, C. D., Gutman, M., Fan, D., Wilson, M. R. and Fidler, I. J. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. *J. Am. Pathol.*, **145**, 365–374 (1994).

29) Nanus, D. M., Schmitz-Draeger, B. J., Motzer, R. J., Lee, A. C., Vlamis, V., Cordon-Cardo, C., Albino, A. P. and Reuter, V. E. Expression of basic fibroblast growth factor in primary human renal tumours: correlation with poor survival. *J. Natl. Cancer Inst.*, **85**, 1597–1599 (1993).

30) Kato, T., Sato, K., Kakinuma, K. and Matsuda, Y. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillin (TNP-470) and cytotoxic agents in mice. *Cancer Res.*, **54**, 5143–5147 (1994).

31) O’Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R. and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *Cell*, **88**, 277–285 (1997).